Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG4399 in Healthy Men
NCT04653467Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG4399 in rheumatoid arthritis (RA) and ulcerative colitis (UC) (6 arms), sponsored by Galapagos NV. Primary endpoint: Treatment-Emergent Adverse Events. Started Nov 2020; status: completed.
02
Drugs
GLPG4399
03
Conditions
rheumatoid arthritis (RA)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04653467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653467.